West Pharmaceutical Services, Inc.
WST
$366.66
-$1.69-0.46%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 695.40M | 732.00M | 747.40M | 753.80M | 716.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 695.40M | 732.00M | 747.40M | 753.80M | 716.60M |
| Cost of Revenue | 465.20M | 453.10M | 459.10M | 462.30M | 445.30M |
| Gross Profit | 230.20M | 278.90M | 288.30M | 291.50M | 271.30M |
| SG&A Expenses | 86.70M | 90.80M | 89.00M | 88.30M | 86.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 300.00K | -3.30M | -400.00K | 300.00K | 400.00K |
| Total Operating Expenses | 569.80M | 559.00M | 564.10M | 567.40M | 548.80M |
| Operating Income | 125.60M | 173.00M | 183.30M | 186.40M | 167.80M |
| Income Before Tax | 131.70M | 171.50M | 190.70M | 189.90M | 163.60M |
| Income Tax Expenses | 16.40M | 34.50M | 29.40M | 34.80M | 23.60M |
| Earnings from Continuing Operations | 115.30M | 137.00M | 161.30M | 155.10M | 140.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 115.30M | 137.00M | 161.30M | 155.10M | 140.00M |
| EBIT | 125.60M | 173.00M | 183.30M | 186.40M | 167.80M |
| EBITDA | 161.20M | 208.90M | 219.00M | 220.50M | 199.40M |
| EPS Basic | 1.57 | 1.85 | 2.17 | 2.09 | 1.88 |
| Normalized Basic EPS | 1.13 | 1.50 | 1.61 | 1.63 | 1.47 |
| EPS Diluted | 1.55 | 1.82 | 2.14 | 2.06 | 1.85 |
| Normalized Diluted EPS | 1.12 | 1.48 | 1.59 | 1.60 | 1.45 |
| Average Basic Shares Outstanding | 73.50M | 74.10M | 74.30M | 74.30M | 74.50M |
| Average Diluted Shares Outstanding | 74.30M | 75.00M | 75.30M | 75.40M | 75.70M |
| Dividend Per Share | 0.20 | 0.20 | 0.19 | 0.19 | 0.19 |
| Payout Ratio | 12.75% | 10.80% | 8.68% | 9.09% | 10.07% |
